Knockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer?

Breast Cancer Research

Table 2 p53 deficiency and mutation mammary tumor phenotypes

Model	Agent	Incidence (%)	Latency	Loss of heterozygosity	References
Trp53 ^-/-	Death from nonmammary tumors				[15, 16, 18]
BALB/c mammary epithelium transplants
Trp53 ^+/+	NT or Pit Stim	0	-		[23]
Trp53 ^-/-	NT	61	50 weeks		[18, 23]
Trp53 ^-/-	Pit Stim	100	37 weeks		[23]
Trp53 ^+/+	DMBA	4	26 weeks		[23]
Trp53 ^-/-	DMBA	60	35 weeks		[23]
Trp53 ^+/+	Pit Stim + DMBA	14	27 weeks		[23]
Trp53 ^-/-	Pit Stim + DMBA	90	25 weeks		[23]
Transgenic FVB WAP-p53-R172H mice
p53-R172H	Pregnancy	10–15	> 1 year		[33]
Wild type	Pit Stim + DMBA	85	33 weeks		[33]
p53-R172H	Pit Stim + DMBA	100	24 weeks		[33]
Trp53 ^+/-
B6x129 Trp53 ^+/+	Pit Stim + DMBA	35	5.0 months		[34]
B6x129 Trp53 ^+/-	Pit Stim + DMBA	40	4.6 months	No	[34]
BALB/c (N9) Trp53 ^+/-	Spontaneous	55	8–14 months	Yes	[18]
BALB/c or DBA/2 Trp53 ^+/+	γ-Radiation	0		-	[35]
DBA/2 (N1-6) Trp53 ^+/-	γ-Radiation	6		Yes	[35]
BALB/c (N1-6) Trp53 ^+/-	γ-Radiation	41		Yes	[35]

DMBA, 7,12-dimethylbenz [a]anthracene; NT, no treatment; Pit Stim, hormonal stimulation provided by pituitary isografts; WAP, whey acidic protein.

ISSN: 1465-542X